Targeting vulnerability in B-cell development leads to novel drug combination for leukemia

By characterizing B-cells’ developmental stages, scientists at St. Jude Children’s Research Hospital designed and tested a drug combination to effectively treat resistant B-cell leukemia.

Read more: https://www.stjude.org/media-resources/news-releases/2024-medicine-science-news/targeting-vulnerability-in-b-cell-development-leads-to-novel-drug-combination-for-leukemia.html